BNB Soars Past $850 to Record High as Wall Street Giants Dive Into Crypto
Institutional money floods Binance Coin—proving even suits can't resist a bull market.
Wall Street's latest love affair? BNB. The token just smashed through $850, riding a wave of fresh capital from hedge funds and asset managers who finally figured out crypto wallets. Who said dinosaurs couldn't adapt?
The surge comes as TradFi players scramble for exposure—better late than never, right? Meanwhile, retail traders watch from the sidelines, muttering about 'institutional validation' between bites of ramen.
One hedge fund VP told us: 'We're long-term bullish' (translation: we bought the top). But with CEX reserves thinning and staking yields juicy, this rally might have legs. Or at least until the next 'macro environment' excuse.
Remember when finance pros called crypto a scam? Now they're YOLO-ing into altcoins. The revolution won't be decentralized—just heavily monetized.
Over $1 billion planned for BNB’s institutional acquisitions
Meanwhile, BNB’s rally is drawing more than just retail enthusiasm as several institutional investors are increasingly positioning themselves for long-term exposure.
On July 28, CEA Industries Inc. (Nasdaq: VAPE) announced plans to launch the world’s largest publicly listed BNB treasury strategy.
CEA aims to become the first regulated, US-listed treasury firm focused on BNB. It is backed by 10X Capital and YZi Labs.
The firm has a $500 million private placement, including $100 million in crypto allocations. If warrants are exercised, the total deal could reach $1.25 billion.
According to the press statement, more than 140 institutions have already participated in the deal, including Pantera Capital, GSR, dao5, and Arrington Capital.
Russell Read, the CIO of CEA, said:
“By creating a treasury vehicle, we’re allowing institutions to participate in that growth story in a way that aligns with their need for transparency and long-term value, rather than short-term trading opportunities.”
Adding to the wave of institutional interest is Liminatus Pharma, a US-based biotech firm.
The company has unveiled plans to launch a dedicated investment arm, “American BNB Strategy,” which will deploy up to $500 million into BNB over time.
According to the firm, the initiative emerged from an internal review of blockchain-integrated financial models and reflects confidence in BNB’s infrastructure, security, and growth trajectory.
Chris Kim, CEO of Liminatus, said:
“This is not a short-term speculative initiative, but rather a value-driven strategy based on the long-term growth potential and strength of the BNB ecosystem.”
